iTeos Therapeutics (ITOS) Competitors

Nurix Therapeutics (NASDAQ:NRIX) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking.

Do institutionals & insiders have more ownership in NRIX or ITOS?

97.2% of iTeos Therapeutics shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in NRIX or ITOS?

Nurix Therapeutics received 36 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 80.70% of users gave iTeos Therapeutics an outperform vote while only 78.10% of users gave Nurix Therapeutics an outperform vote.

Company	Underperform	Outperform
Nurix Therapeutics	Outperform Votes 82 78.10%	Underperform Votes 23 21.90%
iTeos Therapeutics	Outperform Votes 46 80.70%	Underperform Votes 11 19.30%

Which has more risk & volatility, NRIX or ITOS?

Nurix Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.

Which has higher valuation and earnings, NRIX or ITOS?

iTeos Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$54.55M	13.38	-$193.57M	-$2.89	-3.31
iTeos Therapeutics	$35M	5.87	-$112.64M	-$3.31	-1.63

Does the media prefer NRIX or ITOS?

In the previous week, Nurix Therapeutics had 11 more articles in the media than iTeos Therapeutics. MarketBeat recorded 12 mentions for Nurix Therapeutics and 1 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 0.84 beat Nurix Therapeutics' score of 0.45 indicating that iTeos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
iTeos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is NRIX or ITOS more profitable?

iTeos Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. iTeos Therapeutics' return on equity of -20.11% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-354.85%	-53.65%	-38.59%
iTeos Therapeutics	N/A	-20.11%	-17.50%

Do analysts recommend NRIX or ITOS?

Nurix Therapeutics currently has a consensus target price of $30.88, suggesting a potential upside of 222.53%. iTeos Therapeutics has a consensus target price of $25.75, suggesting a potential upside of 378.62%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.83
iTeos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

iTeos Therapeutics beats Nurix Therapeutics on 11 of the 18 factors compared between the two stocks.